Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Indonesian Journal of Pharmaceutical Science and Technology Indonesian Journal of Cancer
Hutapea, Ezra Calista
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Computer Science & IT Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Studi In Silico Potensi Antidiabetes Senyawa pada Black Garlic sebagai Inhibitor Enzim DPP-4 Sudirman, Virgiana Keisha Rajabi Johni; Priana, Diva Dhaifina Mazaya; Puspitasari, Citra Dewi; Hutapea, Ezra Calista; Muntashir, Ilham Mohammad; Pribadi, Alya Puteri Agustina; Parameswari, Natashya; Aulifa, Diah Lia
Indonesian Journal of Pharmaceutical Science and Technology Vol 11, No 2 (2024)
Publisher : Indonesian Journal of Pharmaceutical Science and Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24198/ijpst.v11i2.47506

Abstract

Diabetes mellitus merupakan penyakit kronis yang berkaitan dengan gangguan metabolisme glukosa darah. Black Garlic memiliki potensi sebagai antidiabetes karena mengandung berbagai senyawa yang dapat mengontrol kadar gula darah seperti asam fenolik, senyawa flavonoid dan S-allyl-L-cysteine (SAC). DPP-4 merupakan enzim yang berperan penting sebagai target terapeutik dari gliptin dalam pengobatan diabetes mellitus mellitus tipe II. Penelitian ini dilakukan dengan tujuan membuktikan potensi senyawa pada Black Garlic sebagai inhibitor enzim DPP-4 secara in silico melalui metode penambatan molekuler. Berdasarkan hasil penelitian, SAC memiliki nilai energi ikatan sebesar -5,36 kkal/mol dan nilai konstanta inhibisi sebesar 118,08 μM. Hal ini menunjukkan bahwa ikatan antara senyawa SAC dengan enzim DPP-4 bersifat stabil dan terbukti berpotensi sebagai inhibitor enzim DPP-4 dibandingkan keempat senyawa uji lainnya. Namun, senyawa SAC tidak lebih baik dari ligan alaminya karena memiliki nilai energi ikatan dan konstanta inhibisi yang lebih kecil. Oleh karena itu dapat disimpulkan bahwa senyawa SAC pada Black Garlic tidak lebih efektif dibandingkan dengan ligan alaminya yaitu Vildagliptin tetapi tetap dapat berpotensi sebagai inhibitor enzim DPP-4.
Comparative Review of the Potential of 177Lu-PSMA-617 and Docetaxel Chemotherapy in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Rahmawati, N. Anna Sakinah Liana; Hutapea, Ezra Calista; Holik, Holis Abdul
Indonesian Journal of Cancer Vol 19, No 3 (2025): September
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i3.1296

Abstract

Background: Prostate cancer has witnessed a substantial rise in both prevalence and risk over the years. In 2022, it is expected to rank fourth in terms of annual cancer-related mortality.  The treatment of prostate cancer involves the administration of chemotherapy using conventional drugs such as docetaxel. The most recent advancement in treating metastatic castration-resistant prostate cancer (mCRPC) is 177Lu-PSMA-617, a radioligand therapy. This treatment combines radioactive and ligand elements, resulting in exceptionally effective outcomes. This review aims to compare the potential of 177Lu-PSMA and Docetaxel in terms of production, side effects, prostate-specific antigen (PSA) reduction, and associated costs.Methods:  This literature review examines the differences in the therapeutic effectiveness of 177Lu-PSMA-617 and docetaxel monotherapy or in combination in patients with mCRPC.  Relevant research on both treatment options was searched, focusing on human clinical trials and case reports published between 2010 and 2024. Article selection was conducted in databases such as PubMed, Scopus, Springer, Elsevier, and NCBI.Results: Based on the eight articles included in this review, 177Lu-PSMA-617 can be regarded as an alternative therapy for patients with mCRPC. 177Lu-PSMA-617 and docetaxel can both decrease PSA levels by ≥50%. However, it's important to note that 177Lu-PSMA-617 is more expensive than docetaxel. Furthermore, the adverse effects of 177Lu-PSMA-617 are relatively less severe compared to those of docetaxel.Conclusions: The comparative results between docetaxel and 177Lu PSMA demonstrate that both therapies exhibit similar efficacy in reducing PSA levels. The results indicate that radioligand therapy 177Lu-PSMA-617 can be used as an alternative treatment for mCRPC with the potential for cure and minimal side effects. The cost can be minimized by increasing the utilization of radioligand 177Lu-PSMA-617, as higher usage leads to decreased prices.
Co-Authors Diah Lia Aulifa Holis Abdul Holik, Holis Abdul Muntashir, Ilham Mohammad Parameswari, Natashya Priana, Diva Dhaifina Mazaya Pribadi, Alya Puteri Agustina Puspitasari, Citra Dewi Rahmawati, N. Anna Sakinah Liana Sudirman, Virgiana Keisha Rajabi Johni